HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells

Human cancer cells display extensive heterogeneity in their sensitivities to the proteasome inhibitor bortezomib (Velcade). The molecular mechanisms underlying this heterogeneity remain unclear, and strategies to overcome resistance are limited. Here, we discover that inherent differences in eIF2α p...

Descripción completa

Detalles Bibliográficos
Autores principales: White, Matthew C., Schroeder, Rebecca D., Zhu, Keyi, Xiong, Katherine, McConkey, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138554/
https://www.ncbi.nlm.nih.gov/pubmed/29720726
http://dx.doi.org/10.1038/s41388-018-0227-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138554/
https://www.ncbi.nlm.nih.gov/pubmed/29720726
http://dx.doi.org/10.1038/s41388-018-0227-y

Ejemplares similares